RxDoctor Payments Data

Sanjeev Gulati, MD

Cardiovascular Disease · Charlotte, NCNPI 1578574638

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $263,395 of the $406,004 with a category attached, or 64.9%. 13 manufacturers reported payments, led by Medtronic at 41.4% of the total. Among cardiovascular disease clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$406,004in general payments, 2019–2025

Across 406 payments — averaging $1000.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$168K
  • Abbott$88K
  • Boston Scientific$72K
  • Novartis$36K
  • Procyrion, Inc.$17K
  • Biotronik Inc.$10K
  • plus $15K from 7 others
$157,205in research payments, 2019–2025

Across 88 payments — averaging $1786.43 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Abbott$119K
  • Boston Scientific$34K
  • Medtronic$4K

What the payments were for

  • Consulting fees$97,37124%
  • Speaking & faculty fees$263,39565%
  • Travel & lodging$30,2887%
  • Food & beverage$14,8884%
  • Education$620%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$406,004 in reported general payments places this provider in the 95th percentile of 727 cardiovascular disease providers in North Carolina.

See all cardiovascular disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$13,805
Medicare patients
58
Services billed
114

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan47$63,492
JardianceEmpagliflozin35$32,716
Dapsone11$544
Carvedilol33$408
Torsemide13$346
Metoprolol Succinate13$232
Spironolactone30$221
Atorvastatin Calcium15$210
Amlodipine Besylate14$141
Furosemide32$125
Potassium Chloride11$107
Prednisone13$106

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$36,442$63,49247 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 727 cardiovascular disease providers in North Carolina.

Other cardiovascular disease in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →